



Clearside Biomedical to Present at the 37th Annual J.P. Morgan Healthcare Conference

January 2, 2019

ALPHARETTA, Ga., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its Chief Executive Officer and President, Daniel White, will present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 8:30 a.m. PST at the Westin St. Francis Hotel in San Francisco, CA.

A live webcast of the presentation can be accessed on the company's website at www.clearsidebio.com under the "Events & Presentations" tab in the "Investor Relations" section. Following the conference, the presentation webcast will be archived on the website for approximately 90 days.

About Clearside

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases. Clearside's proprietary suprachoroidal treatment approach offers unprecedented access to the back of the eye where sight-threatening disease often occurs. The company's unique platform for eye disease treatments is inherently flexible and intended to work with established medicines, new formulations of medicines, as well as future innovations such as gene therapy. Clearside is headquartered in Alpharetta, GA. For more information, please visit <http://www.clearsidebio.com>. Follow @clearsidebio on Twitter and LinkedIn.

Contacts:

Stephen Kilmer
Investor Relations
(678) 430-8206
stephen.kilmer@clearsidebio.com

Charles Deignan
Chief Financial Officer
678-270-4005
charlie.deignan@clearsidebio.com



Source: Clearside Biomedical, Inc.